WO2002004086A1 - Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions - Google Patents

Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions Download PDF

Info

Publication number
WO2002004086A1
WO2002004086A1 PCT/US2000/016326 US0016326W WO0204086A1 WO 2002004086 A1 WO2002004086 A1 WO 2002004086A1 US 0016326 W US0016326 W US 0016326W WO 0204086 A1 WO0204086 A1 WO 0204086A1
Authority
WO
WIPO (PCT)
Prior art keywords
ion
titanium
zirconium
value
blood
Prior art date
Application number
PCT/US2000/016326
Other languages
French (fr)
Inventor
John D. Sherman
Gregory J. Lewis
David S. Bem
Original Assignee
Uop Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uop Llc filed Critical Uop Llc
Priority to EP00946802A priority Critical patent/EP1307270A1/en
Priority to JP2002508537A priority patent/JP2004502508A/en
Priority to AU2000260501A priority patent/AU2000260501A1/en
Priority to PCT/US2000/016326 priority patent/WO2002004086A1/en
Publication of WO2002004086A1 publication Critical patent/WO2002004086A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/24Dialysis ; Membrane extraction
    • B01D61/243Dialysis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1694Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid
    • A61M1/1696Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid with dialysate regeneration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287Dialysates therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02Processes using inorganic exchangers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/10Oxides or hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation

Definitions

  • Dialysis is defined as the removal of substances from a liquid by diffusion across a semipermeable membrane into a second liquid. Dialysis of blood outside of the body (hemodialysis) is the basis of the "artificial kidney.” The artificial kidney treatment procedure generally used today is similar to that developed by Kolff in the early 1940s.
  • U.S.-A- 4581141 discloses a composition for use in dialysis which contains a surface adsorptive substance, water, a suspending agent, urease, a calcium-l ⁇ aded cation exchanger, an aliphatic carboxylic acid resin and a metabolizable organic acid buffer.
  • the calcium loaded cation exchanger can be a calcium- exchanged zeolite.
  • EP 0 046 971 A1 discloses that zeolite W can be used in hemodialysis to remove ammonia.
  • US-A-5536412 discloses hemofiltration and plasmafiltration devices in which blood flows through the interior of a hollow fiber membrane and during the flow of blood, a sorbent - suspension is circulated against the exterior surfaces of the hollow fiber membrane.
  • the sorbent can be activated charcoal along with an ion- exchanger such as a zeolite or a cation-exchange resin.
  • charcoal does not remove any water, phosphate, sodium or other ions.
  • Zeolites have the disadvantage that they can partially dissolve in the dialysis solution, allowing aluminum and/or silicon to enter the blood. Additionally, zeolites can adsorb sodium, calcium and potassium ions from the blood thereby requiring that these ions be added back into the blood.
  • microporous ion exchangers which are essentially insoluble in neutral or basic pH fluids, such as bodily fluids (especially blood) or dialysis solutions.
  • These microporous ion exchangers have an empirical formula on an anhydrous basis of:
  • This invention relates to a process for removing toxins from fluids selected from the group consisting of blood or a dialysate solution.
  • the process comprises contacting the fluid containing the toxins extracorporial or in vitro with a microporous ion exchanger at ion exchange conditions thereby removing the toxins from the fluid, the microporous ion exchanger selected from the group consisting of zirconium metallate,, titanium metallate and mixtures thereof, the metallates respectively having an empirical formula on an anhydrous basis of:
  • A is an exchangeable cation selected from the group consisting of potassium ion, sodium ion, calcium ion, magnesium ion and mixtures thereof
  • M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+), except that M is not titanium in formula ( ⁇ ), "p” has a value from 1 to 20, “x” has a value from zero to less than 1 , "n” has a value from 0 to 12, “y” has a value from 0 to 12, “m” has a value from 3 to 36 and 1 ⁇ n + y ⁇ 12.
  • Alkali sources include potassium hydroxide, sodium hydroxide, rubidium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, rubidium carbonate, cesium carbonate, sodium halide, potassium halide, rubidium halide, cesium halide, sodium ethylenediamine tetraacetic acid (EDTA), potassium EDTA, rubidium EDTA, and cesium EDTA.
  • the M metals sources include the M metal oxides, alkoxides, halide salts, acetate salts, nitrate salts and sulfate salts.
  • M metal sources include, but are not limited to titanium alkoxides, titanium tetrachloride, titanium trichloride, titanium dioxide, tin tetrachloride, tin isopropoxide, niobium isopropoxide, hydrous niobium oxide, hafnium isopropoxide, hafnium chloride, hafnium oxychloride, cerium chloride, cerium oxide and cerium sulfate.
  • the titanium metallates are prepared in an analogous manner to the zirconium metallates.
  • the sources of silicon, germanium, M metal and alkali metal are as enumerated above.
  • the titanium source is also as enumerated above, namely titanium alkoxides, titanium tetrachloride, titanium trichloride and titanium dioxide.
  • a preferred titanium source is titanium alkoxides with specific examples being titanium isopropoxide, titanium ethoxide and titanium butoxide ' . ⁇ .
  • the hydrothermal process used to prepare the zirconium metallate or titanium metallate ion exchange compositions used in this invention involves forming a reaction mixture which in terms of molar ratios of the oxides is expressed by the formulae:
  • reaction mixture is prepared by mixing the desired sources of zirconium, silicon and optionally germanium, alkali metal and optional M metal in any order to give the desired mixture. It is also necessary that the mixture have a basic pH and preferably a pH of at least 8. The basicity of the mixture is controlled by adding excess alkali hydroxide and/or basic compounds of the other constituents of the mixture.
  • reaction mixture it is next reacted at a temperature of 100°C to 250°C for a period of 1 to 30 days in a sealed reaction vessel under autogenous pressure. After the allotted time, the mixture is filtered to isolate the solid product which is washed with deionized water and dried in air.
  • microporous ion exchangers have a large capacity and selectivity for removing ammonium ions from the dialysate fluid.
  • the urease can of course be immobilized on the microporous ion exchange compositions of the present invention. Details regarding bonding of urease to microporous compositions can be found in US- A-4581141 which is incorporated by reference.
  • Another extracorporeal process uses a dialysate regeneration system called a REDY cartridge.
  • the cartridge contains a system of sorbents including activated carbon, zirconium phosphate and hydrous zirconium oxide.
  • V volume of test dialysate (mL)

Abstract

A process for removing toxins from fluids such as blood or a dialysate solution, is disclosed. The process involves contacting the fluid with a microporous ion exchanger to remove toxins in the fluid. The microporous ion exchangers are represented by the following empirical formulae (I) and (II): ApMxZr1-xSinGeyOm (I) and ApMxTi1-xSinGeyOm (II).

Description

"PROCESS FOR REMOVING TOXINS FROM BODILY FLUIDS USING ZIRCONIUM or TITANIUM MICROPOROUS COMPOSITIONS"
BACKGROUND
In mammals, e.g., humans, when the kidneys and/or liver fail to remove metabolic waste products from the body, most of the other organs of the body also soon fail. Accordingly, extensive efforts have been made to discover safe and effective methods for removing toxins from patients' blood by extracorporeal treatment of the blood. Many methods have been proposed for removing small molecular toxins, protein-bound molecules or larger molecules thought to be responsible for the coma and illness of hepatic failure. Some of these toxic compounds have been identified as urea, creatine, ammonia, phenols, mercaptans, short chain fatty acids, aromatic amino acids, false neural transmitters (octopamine), neural inhibitors (glutamate) and bile salts. Among these, phenols and mercaptans, along with bilirubin and bacterial endotoxins, also occur as strong protein-bound toxins and are thus more difficult to effectively remove from the blood. Middle molecular weight toxins having a molecular weight of about 300 to about 10,000 can also be present and are difficult to effectively remove.
The art shows a number of ways to treat blood containing such toxins. The classic method is of course dialysis. Dialysis is defined as the removal of substances from a liquid by diffusion across a semipermeable membrane into a second liquid. Dialysis of blood outside of the body (hemodialysis) is the basis of the "artificial kidney." The artificial kidney treatment procedure generally used today is similar to that developed by Kolff in the early 1940s.
Since the 194ξ).s there have been a number of disclosures which deal with improvements pn artificial kidneys or artificial livers. Thus, U.S.-A- 4261828 discloses an apparatus for the detoxification of blood. The apparatus comprises a housing filled with an adsorbent such as charcoal or a resin and optionally an enzyme carrier. In order to prevent direct contact between the blood and the adsorbent, the adsorbent may be coated with a coating which is permeable for the substances to be adsorbed yet prevent the direct contact between the corpuscular blood components, and the adsorbents. U.S.-A- 4581141 discloses a composition for use in dialysis which contains a surface adsorptive substance, water, a suspending agent, urease, a calcium-lόaded cation exchanger, an aliphatic carboxylic acid resin and a metabolizable organic acid buffer. The calcium loaded cation exchanger can be a calcium- exchanged zeolite. EP 0 046 971 A1 discloses that zeolite W can be used in hemodialysis to remove ammonia. Finally, US-A-5536412 discloses hemofiltration and plasmafiltration devices in which blood flows through the interior of a hollow fiber membrane and during the flow of blood, a sorbent - suspension is circulated against the exterior surfaces of the hollow fiber membrane. Another step involves having the plasma fraction of the blood alternately exit and re-enter the interior of the membrane thereby effectuating removal of toxins. The sorbent can be activated charcoal along with an ion- exchanger such as a zeolite or a cation-exchange resin.
There are problems associated with the adsorbents disclosed in the above patents. For example, charcoal does not remove any water, phosphate, sodium or other ions. Zeolites have the disadvantage that they can partially dissolve in the dialysis solution, allowing aluminum and/or silicon to enter the blood. Additionally, zeolites can adsorb sodium, calcium and potassium ions from the blood thereby requiring that these ions be added back into the blood.
Applicants have developed a process which uses microporous ion exchangers which are essentially insoluble in neutral or basic pH fluids, such as bodily fluids (especially blood) or dialysis solutions. These microporous ion exchangers have an empirical formula on an anhydrous basis of:
ApMxZri-xSiπGβyOm (I) or
ApMxTH-xSinGθyOm (π)
where A is an exchangeable cation selected from the group consisting of potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+), except that M is not titanium in formula (π), "p" has a value from 1 to 20, "x" has a value from zero to less than 1 , "n" has a value from 0 to 12, "y" has a value from 0 to about 12, "m" has a value from 3 to 36 and 1 < n + y ≤ 12. The germanium can substitute for the silicon, zirconium/titanium or combinations thereof.
SUMMARY
This invention relates to a process for removing toxins from fluids selected from the group consisting of blood or a dialysate solution. The process comprises contacting the fluid containing the toxins extracorporial or in vitro with a microporous ion exchanger at ion exchange conditions thereby removing the toxins from the fluid, the microporous ion exchanger selected from the group consisting of zirconium metallate,, titanium metallate and mixtures thereof, the metallates respectively having an empirical formula on an anhydrous basis of:
ApMxZrLxSinGeyOm (I) and
ApMxTi1-xSinGeyOm (π)
where A is an exchangeable cation selected from the group consisting of potassium ion, sodium ion, calcium ion, magnesium ion and mixtures thereof, M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+), except that M is not titanium in formula (π), "p" has a value from 1 to 20, "x" has a value from zero to less than 1 , "n" has a value from 0 to 12, "y" has a value from 0 to 12, "m" has a value from 3 to 36 and 1 < n + y < 12.
This and other objects and embodiments will become more clear after a detailed description of the invention. DETAILED DESCRIPTION
As stated, applicants have developed a new process for removing various toxins from fluids selected from blood and dialysate solution. One essential element of the instant process is a microporous ion exchanger which has a large capacity and strong affinity, i.e., selectivity for at least ammonia. These microporous compositions are identified as zirconium metallate and titanium metallate compositions. They are further identified by their empirical formulas (on an anhydrous basis) which respectively are:
ApMxZr1-xSinGeyOm (I) or
ApMxTiι-xSinGeyOm (H)
In the case of formula I, the composition has a microporous framework structure composed of Zr03 octahedral units and at least one of Si02 tetrahedral units and Ge02 tetrahedral units. In the case of formula π, the microporous framework structure is composed of Ti03 octahedral units and at least one of Si02 tetrahedral units and Ge02 tetrahedral units.
In both formulas I and π, A is an exchangeable cation selected from the group consisting of potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+), "p" has a value from 1 to 20, "x" has a value from zero to less than 1 , "n" has a value from 0 to 12, "y" has a value from 0 to about 12, "m" has a value from 3 to 36 and the sum of n + y has a value from 1 to 12. That is 1 < n + y ≤ 12. In equation (π) M is, of course, not titanium. The M metals which can be inserted into the framework in place of zirconium will be present as M03 octahedral units and thus it is a requirement that they are capable of being octahedrally coordinated. The germanium can be inserted into the framework in place of silicon and will be present as M02 tetrahedral units. Additionally, germanium can be inserted into the framework as a M03 octahedral unit replacing some of the zirconium in formula (I) or some of the titanium in formula (LX).. That is, , germanium can replace some or all of the silicon, some of the zirconium in formula (I), some of the titanium in formula (LT) or both silicon and zirconium or both silicon and titanium.
The zirconium metallates are prepared by a hydrothermal crystallization of a reaction mixture prepared by combining a reactive source of zirconium, silicon and/or germanium, optionally one or more M metal, at least one alkali metal and water. The alkali metal acts as a templating agent. Any zirconium compound, which can be hydrolyzed to zirconium oxide or zirconium hydroxide, can be used. Specific examples of these compounds include zirconium alkoxide, e.g., zirconium n-propoxide, zirconium hydroxide, zirconium acetate, zirconium oxychloride, zirconium chloride, zirconium phosphate and zirconium oxynitrate. The sources of silica include colloidal silica, fumed silica and sodium silicate. The sources of germanium include germanium oxide, germanium alkoxides and germanium tetrachloride. Alkali sources include potassium hydroxide, sodium hydroxide, rubidium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, rubidium carbonate, cesium carbonate, sodium halide, potassium halide, rubidium halide, cesium halide, sodium ethylenediamine tetraacetic acid (EDTA), potassium EDTA, rubidium EDTA, and cesium EDTA. The M metals sources include the M metal oxides, alkoxides, halide salts, acetate salts, nitrate salts and sulfate salts. Specific examples of the M metal sources include, but are not limited to titanium alkoxides, titanium tetrachloride, titanium trichloride, titanium dioxide, tin tetrachloride, tin isopropoxide, niobium isopropoxide, hydrous niobium oxide, hafnium isopropoxide, hafnium chloride, hafnium oxychloride, cerium chloride, cerium oxide and cerium sulfate.
The titanium metallates are prepared in an analogous manner to the zirconium metallates. Thus, the sources of silicon, germanium, M metal and alkali metal are as enumerated above. The titanium source is also as enumerated above, namely titanium alkoxides, titanium tetrachloride, titanium trichloride and titanium dioxide. A preferred titanium source is titanium alkoxides with specific examples being titanium isopropoxide, titanium ethoxide and titanium butoxide'. \ .
Generally, the hydrothermal process used to prepare the zirconium metallate or titanium metallate ion exchange compositions used in this invention involves forming a reaction mixture which in terms of molar ratios of the oxides is expressed by the formulae:
a A20: b MOq 2: 1 - b Zr 02: c Si02: d Ge02: e H2 O (ITJ) and a A20: b MOq 2: 1 - b Ti 02: c Si02: d Ge02: e H2 O (IN)
where "a" has a value from 0.25 to 40, "b" has a value from 0 to 1 , "q" is the valence of M, "c" has a value from 0.5 to 30, "d" has a value from 0 to 30 and "e" has a value of 10 to 3000. The reaction mixture is prepared by mixing the desired sources of zirconium, silicon and optionally germanium, alkali metal and optional M metal in any order to give the desired mixture. It is also necessary that the mixture have a basic pH and preferably a pH of at least 8. The basicity of the mixture is controlled by adding excess alkali hydroxide and/or basic compounds of the other constituents of the mixture. Having formed the reaction mixture it is next reacted at a temperature of 100°C to 250°C for a period of 1 to 30 days in a sealed reaction vessel under autogenous pressure. After the allotted time, the mixture is filtered to isolate the solid product which is washed with deionized water and dried in air.
As stated the microporous compositions of this invention have a framework structure of octahedral Zr03 units, at least one of tetrahedral Si02 units and tetrahedral Ge02 units and optionally octahedral O3 units. This framework results in a microporous structure having an intracrystalline pore system with uniform pore diameters, i.e., the pore sizes are crystallographically regular. The diameter of the pores can vary considerably from about 3 A and larger. The x-ray diffraction pattern of various titanium and zirconium metallates is presented in US-A-5,891 ,417.
As synthesized, the microporous compositions used this invention will contain some of the alkali metal templating agent in the pores. These metals are described as exchangeable cations, meaning that they can be exchanged with other (secondary) A' cations!: Generally, the A exchangeable cations can be exchanged with A' cations selected from other alkali metal cations (K+, Na+, Rb+, Cs+), alkaline earth cations (Mg2+, Ca2+, Sr2+, Ba2+), hydronium ion or mixtures thereof. It is understood that the A' cation is different from the A cation. The methods used to exchange one cation for another are well known in the art and involve contacting the microporous compositions with a solution containing the desired cation (at molar excess) at exchange conditions. Exchange conditions include a temperature of 25°C to 100°C and a time of 20 minutes to 2 hours. The particular cation (or mixture thereof) which is present in the final product will depend on the particular use and the specific composition being used. One specific composition is an ion exchanger where the A' cation is a mixture of Na+, Ca+2 and H+ ions.
It is also within the scope of the invention that these microporous ion exchange compositions can be used in powder form or can be formed into various shapes with or without a binder by means well known in the art. Examples of these various shapes include pills, extrudates, spheres, pellets and irregularly shaped particles.
As stated, these compositions have particular utility in adsorbing various toxins from fluids selected from blood or dialysate solutions. The instant process is particularly suited for removing toxins from human blood. Of course, blood from other mammals such as cows, pigs, sheep, dogs, etc. can also be purified.
There are a number of means for directly or indirectly contacting the fluids with the desired ion exchanger and thus, remove the toxins. One technique is hemoperfusion, which involves packing the above described microporous ion exchange composition into a column through which blood is flowed. One such system is described in US-A-4261828 which is incorporated by reference. As stated in the '828 patent, the microporous ion exchange composition is preferably formed into desired shapes such as spheres. Additionally, the microporous ion exchange composition particles can be coated with compounds, such as cellulose derivatives, which are compatible with the blood but nonpermeable for corpuscular blood components. In one specific case, spheres of the dέsired ion exchange compositions described above can be packed into hollow fibers thereby providing a semipermeable membrane. It should also be pointed out that more than one type of molecular sieve can be mixed and used in the process in order to enhance the efficiency of the process.
Another way of carrying out the process is to prepare a suspension or slurry of the molecular sieve adsorbent by means known in the art such as described is US-A-5536412 which is incorporated by reference. The apparatus described in the '412 patent can also be used to carry out the process. The process basically involves passing a fluid, e.g. blood, containing toxins through the interior of a hollow fiber and during said passing circulating a sorbent suspension against the exterior surfaces of the hollow fiber membrane. ,At the same time, intermittent pulses of positive pressure are applied to the sorbent solution so that the fluid alternately exits and re-enters the interior of the hollow fiber membrane thereby removing toxins from the fluid.
The instant microporous ion exchange, compositions can also be used in a conventional dialysis process where the blood is first contacted with a dialysis solution (dialysate) to remove uremic substances from the blood. The dialysate is now regenerated and recirculated. Regeneration is carried out by contacting the urea containing dialysate with urease to convert the urea to ammonium ion and carbonate ion according to the equation:
2H20 + H4N2CO → 2NH4 + + C03 =
In order for this reaction to < proceed to completion, ammonium ions and carbonate ions must be removed. In the instant process, the microporous ion exchangers have a large capacity and selectivity for removing ammonium ions from the dialysate fluid. The urease can of course be immobilized on the microporous ion exchange compositions of the present invention. Details regarding bonding of urease to microporous compositions can be found in US- A-4581141 which is incorporated by reference. Another extracorporeal process uses a dialysate regeneration system called a REDY cartridge. The cartridge contains a system of sorbents including activated carbon, zirconium phosphate and hydrous zirconium oxide. The ammonium ions which are formed per the process described above using urease are absorbed by the zirconiurn phosphate in exchange for hydrogen and sodium ions. A description of the REDY cartridge may be found in a paper by A. Gordon and M. Roberts, published in Sorbents and Their Clinical Applications, C. Giordano editor, Academic Press, pp. 249-273 (1980) and especially p. 263-4 all of which are incorporated by reference.
Another type of dialysis is peritoneal dialysis. In peritoneal dialysis, the peritoneal cavity or the abdominal cavity (abdomen) is filled via a catheter inserted into the peritoneal cavity with a dialysate fluid or solution which contacts the peritoneum. Toxins and excess water flow from the blood through the peritoneum, which is a membrane that surrounds the outside of the organs in the abdomen, into the dialysate fluid. The dialysate remains in the body for a time (dwell time) sufficient to remove the toxins. After the required dwell time, the dialysate is removed from the peritoneal cavity through the catheter. There are two types of peritoneal dialysis. In continuous ambulatory peritoneal dialysis (CAPD), dialysis is carried out throughout the day. The process involves maintaining the dialysate solution in the peritoneal cavity and periodically removing the spent dialysate (containing toxins) and refilling the cavity with a fresh dialysate solution. This is carried out several times during the day. The second type is automated peritoneal dialysis or APD. In APD, a dialysate solution is exchanged by a device at night while the patient sleeps. In both types of dialyses, a fresh dialysate solution must be used for each exchange.
The zirconium and titanium metallates of the present invention can be used to regenerate the dialysate solutions used in peritoneal dialysis, thereby further decreasing the amount of dialysate that is needed to cleanse the blood and/or the amount of time needed to carry out the exchange. This regeneration is carried out by any of the means described above for conventional dialysis. For example, in an indirect contacting process, the dialysate from the peritoneal cavity, i.e. first dialysate is contacted with urease and the ammonium ions transferred across a membrane, thereby purifying the first dialysate solution, i.e. a purified dialysate solution. The second dialysate solution is flowed through at least one adsorption bed containing at least one microporous ion exchanger described above, thereby removing the ammonia and yielding a purified second dialysate solution. It is usually preferred to continuously circulate the second dialysate solution through the adsorbent bed until all of the ammonium ions have been removed. It is also preferred that the first dialysate solution be circulated through the peritoneal cavity, thereby increasing the ammonia removal efficiency and decreasing the total dwell time.
A direct contacting process can also be carried out in which the first dialysate solution is introduced into the peritoneal cavity and then flowed through at least one bed containing at least one microporous ion exchanger. As described above, this can be carried out as CAPD or APD.
The composition of the dialysate solution can be varied in order to ensure a proper electrolyte balance in the body. This is well known in the art along with various apparatus for carrying out the dialysis.
As has also been stated, although the instant compositions are synthesized with a variety of exchangeable cations ("A"), it is preferred to exchange the cation with secondary cations (A') which are more compatible with blood or do not adversely affect the blood. For this reason, preferred cations are sodium, calcium, hydronium and magnesium. Preferred compositions are those containing sodium and calcium or sodium, calcium and hydronium ions. The relative amount of sodium and calcium can vary considerably and depends on the microporous composition and the concentration of these ions in the blood.
In order to more fully illustrate the invention, the following examples are set forth. It is to be understood that the examples are only by way of illustration and are not intended as an undue limitation on the broad scope of the invention as set forth in the appended claims. EXAMPLE 1
A solution was prepared by mixing 2058 g of colloidal silica (DuPont Corp. identified as Ludox® AS-40), 2210 g of KOH in 7655 g H20. After several minutes of vigorous stirring 1471 g of a zirconium acetate solution (22.1 wt.% Zr02) were added. This mixture was stirred for an additional 3 minutes and the resulting gel was transferred to a stainless steel reactor and hydrothermally reacted for 36 hours at 200°C. The reactor was cooled to room temperature and the mixture was vacuum filtered to isolate solids which were washed with deionized water and dried in air.
The solid reaction product was analyzed and found to contain 21.2 wt.% Si, 21.5 wt.% Zr, K 20.9 wt.% K, LOI 12.8 wt.%, which gave a formula of K2.3ZrSi3.2Og.5*3.7H20. This product was identified as sample A.
EXAMPLE 2
A solution was prepared by mixing 121.5 g of colloidal silica (DuPont Corp. identified as Ludox® AS-40), 83.7 g of NaOH in 1051 g H20. After several minutes of vigorous stirring 66.9 g zirconium acetate solution (22.1 wt.% Zr02) was added. This was stirred for an additional 3 minutes and the resulting gel was transferred to a stainless steel reactor and hydrothermally reacted with stirring for 72 hours at 200°C. The reactor was cooled to room temperature and the mixture was vacuum filtered to isolate solids which were washed with deionized water and dried in air.
The solid reaction product was analyzed and found to contain 22.7 wt.% Si, 24.8 wt.% Zr, 12.8 wt.% Na, LOI 13.7 wt.%, which gives a formula Na2.0ZrSi3.oOg.o*3.5H20. This product was identified as sample B.
EXAMPLE 3
A solution (60.08 g) of colloidal silica (DuPont Corp. identified as Ludox® AS-40) was slowly added over a period of 15 minutes to a stirring solution of 64.52 g of KOH dissolved in 224 g deionized H20. This was followed by the addition of 45.61 g zirconium acetate (Aldrich 15-16 wt.% Zr, in dilute acetic acid). When this addition was complete, 4.75 g hydrous Nb205 (30 wt.% LOI) was added and stirred for an additional 5 minutes. The resulting gel was transferred to a stirred autoclave reactor and hydrothermally treated for 1 day at 200°C. After this time, the reactor was cooled to room temperature, the mixture was vacuum filtered, the solid washed with deionized water and dried in air.
The solid reaction product was analyzed and found to contain 20.3 wt.% Si, 15,6 wt.% Zr, 20.2 wt.% K, 6.60 wt.% Nb, LOI 9.32 wt.%, which give a formula of K24Zr0. ι bo.29Si3θ9.2»2.32 H20. Scanning Electron Microscopy (SEM) of a portion of the sample, including EDAX of a crystal, indicated the presence of niobium, zirconium, and silicon framework elements. This product was identified as sample C.
EXAMPLE 4
Ge02 (44.62 g) was slowly added to a stirring solution of 30.50 g of KOH dissolved in 140 g deionized H20. After the addition was complete, 45.82 g ZrOCI2»8H20 dissolved in 140 g deionized H20 was added drop-wise. The resulting gel was transferred to a stirred autoclave reactor and hydrothermally treated for 1 days at 200°C. After this time, the reactor was cooled to room temperature and the mixture was vacuum filtered, the solid was washed with deionized water and dried in air.
The solid reaction product was analyzed and found to contain 41.0 wt.% Ge, 18.4 wt.% Zr, 12.0 wt.% K, LOI 6.39 wt.%, which gave a formula of Kι.52ZrGe2.88.36'1 -84H20. This product was identified as sample D.
EXAMPLE 5
Into a 2-liter beaker, 350.0 g of tetraethylorthosilicate (98%) and 160.83 g of titanium tetraisopropoxide (97%) were placed and stirred with a high speed mechanical mixer. Separately, 106.30 g KOH (87%) was dissolved in 768.5 g of deionized water. This solution was then added to the stirring alkoxides and agitated for an additional two hours. The reaction mixture was then transferred to a 2-liter stirred autoclave where it was digested at a temperature of 200°C for 132 hr. while stirring at 100 rpm. The product was isolated by filtration, washed thoroughly with deionized water and dried at 100°C.
Elemental analysis of the product gave an empirical formula of K1.95Si2.94Ti 08.85. X-ray diffraction analysis showed that this product had the same topology as the mineral umbite. This product was identified as sample E.
EXAMPLE 6
Into a 2-liter beaker, there were mixed 380.0 g of tetraethylorthosilicate (98%) and 104.8 g of titanium tetraisopropoxide (97%). Separately, a sodium hydroxide solution was prepared by dissolving 58.90 g NaOH (97%) in 854.73 g deionized water. This solution was added to the alkoxide mixture as it was stirred vigorously with a mechanical stirrer. The reaction mixture was stirred for 2 hours before it was introduced into a 2-liter autoclave. The reaction mixture was reacted at 200°C at autogenous pressure for 132 hrs. The product was isolated by filtration, washed with deionized water, and dried at 100°C.
Elemental analysis showed that this product had the empirical formula Na2.o5Si3.72TiOιo.47- X-ray diffraction analysis showed that this product had the same topology as the mineral zorite. This product was identified as sample F.
EXAMPLE 7
Samples A to F and zeolite W (obtained from UOP LLC) were tested for removal of ammonium ions using the following procedure. If the compositions were not synthesized in the sodium form (zeolite W was obtained in the potassium form), the compositions were converted to the predominantly sodium form by contacting the compositions with a solution containing a molar excess (at least 10 fold) of sodium chloride thereby exchanging the sodium for the potassium. The exchange conditions were those typical in the art. A test solution was prepared by mixing 6 mL of a dialysate concentrate with 194 mL of deionized water and 0.7 g of ammonium chloride (NH4CI). The final composition of this dialysate test solution is shown in Table 1.
Table 1 Dialysate Test Solution Composition
Figure imgf000015_0001
Into a 25 mL vial, there were added 100 mg of the sample to be tested, to which there were added 10 ml of the above test dialysis solution. The vial was placed in an upright shaker and agitated at 37°C for about 10-18 hours. The mixture was then filtered and the filtrate analyzed for NH4 + concentration by ion chrornatography. Based on this analysis, the particular sample's ability to ion exchange ammonium ions was determined by calculating the ammonium (NH4 +) distribution coefficient (Kd) by using the following formula:
(V)(Ac)
Kd (ml/g) = (WXSc)
where: V = volume of test dialysate (mL)
Ac = concentration of cation absorbed on ion-exchanger (g/mL)
W = mass of ion-exchanger evaluated (g)
Sc = concentration of cation in post reaction supernate (g/mL) The results of the testing are presented in Table 2. Table 2 Ammonium K for several molecular sieves
Figure imgf000016_0001
The results in Table 2 show that the compositions of the present invention have a wide range of Kd for ammonium ion and are suitable for removing toxins from blood.
EXAMPLE 8
To a solution prepared by mixing 141.9 g of NaOH pellets in 774.5 g of water, there were added 303.8 g of sodium silicate with stirring. To this mixture there were added dropwise, 179.9 g of zirconium acetate (15% Zr in a 10% acetic acid solution). After thorough blending, the mixture was transferred to a Hastalloy™ reactor and heated to 200°C under autogenous pressure with stirring for 72 hours. At the end of the reaction time, the mixture was cooled to room temperature, filtered and the solid product was washed with a 0.001 M NaOH solution and then dried at 100°C for 16 hours. Analysis by x-ray powder diffraction showed that the product was pure UZSi-11 (See US-A-5,891 ,417).
EXAMPLE 9
To a container there was added a solution of 37.6 g NaOH pellets dissolved in 848.5 g water and to this solution there were added 322.8 g of sodium silicate with mixing. To this mixture there were added dropwise 191.2 g of zirconium acetate (15% Zr in 10% acetic acid). After thorough blending, the mixture was transferred to a Hastalloy™ reactor and the reactor was heated to 200°C under autogenous conditions with stirring for 72 hours. Upon cooling, the product was filtered, washed with 0.001 M NaOH solution and then dried at 100°C for 16 hours. X-ray powder diffraction analysis showed the product to be UZSi-9 (See US-A-5,891 ,417).
EXAMPLE 10
Samples of UZSi-11 , UZSi-9 and Zr phosphate taken from a REDY cartridge were tested for ammonia adsorption using a similar test to that described in Example 7. A dialysate solution containing the following ions was used for the test: 0.096 wt.% NH4 +; 0.29 wt.% Na+; 0.003 wt.% K+; 0.0017 wt.% Mg and 0.0048 wt.% Ca. To a vial there were added 0.02 g of the sample and 10 ml of dialysate solution. The vial was placed in an upright shaker and agitated for 1440 minutes. The mixture was then filtered and the filtrate analyzed for NH + concentration by ion chromatography. Kd values were calculated as in example 7. The results for these samples are presented in Table 3.
Table 3 Ammonium Kπ for Different Adsorbents
Figure imgf000017_0001

Claims

CLAIMS:
1 ) An in vitro process for removing toxins from a fluid selected from blood or a dialysate solution, the process comprising directly or indirectly contacting the fluid containing the toxins with a microporous ion exchanger at ion exchange conditions thereby removing the toxins from the fluid, the microporous ion exchanger selected from the group consisting of zirconium metallate, titanium metallate and mixtures thereof, the metallates respectively having an empirical formula on an anhydrous basis of:
ApMxZr1-xSinGeyOm (I) and ApMxTi1-xSinGeyOm (ϋ)
where A is an exchangeable cation selected from the group consisting of potassium ion, sodium ion, calcium ion, magnesium ion and mixtures thereof, M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+), except that M is not titanium in formula (II), "p" has a value from 1 to 20, "x" has a value from zero to less than 1 , "n" has a value from 0 to 12, "y" has a value from 0 to 12, "m" has a value from 3 to 36 and 1 < n + y ≤ 12.
2) The process of claim 1 where the fluid is a blood.
3) The process of claim 1 where the fluid is a dialysate solution.
4) The process of claims 1 , 2 or 3 where the toxin is ammonium ion.
5) The process of any of claims 1 to 4 where the microporous ion exchanger has the stucture of UZSi-9.
6) The process of any of claims 1 to 5 where n = 0.
7) The process of any of claims 1 to 6 where the A cation is exchanged for a different secondary cation, A', selected from the group consisting of alkali metals, alkaline earth metal, hydronium ions and mixtures thereof. ) The process of any of claim 1 to 7 where A' is a mixture of sodium and calcium ions.
9) The process of any of claim 1 to 8 where A' is a mixture of sodium, calcium and hydronium ions.
PCT/US2000/016326 2000-07-12 2000-07-12 Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions WO2002004086A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00946802A EP1307270A1 (en) 2000-07-12 2000-07-12 Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
JP2002508537A JP2004502508A (en) 2000-07-12 2000-07-12 Method for removing toxins from body fluids using zirconium or titanium microporous compositions
AU2000260501A AU2000260501A1 (en) 2000-07-12 2000-07-12 Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
PCT/US2000/016326 WO2002004086A1 (en) 2000-07-12 2000-07-12 Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/016326 WO2002004086A1 (en) 2000-07-12 2000-07-12 Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions

Publications (1)

Publication Number Publication Date
WO2002004086A1 true WO2002004086A1 (en) 2002-01-17

Family

ID=21741485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016326 WO2002004086A1 (en) 2000-07-12 2000-07-12 Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions

Country Status (4)

Country Link
EP (1) EP1307270A1 (en)
JP (1) JP2004502508A (en)
AU (1) AU2000260501A1 (en)
WO (1) WO2002004086A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7920884B2 (en) 2004-06-04 2011-04-05 Qualcomm Incorporated Frame structures for a wireless communication system with multiple radio technologies
US8640887B2 (en) 2008-10-03 2014-02-04 Fresenius Medical Care Holdings, Inc. Zirconium phosphate particles having improved adsorption capacity and method of synthesizing the same
EP3246287A1 (en) * 2011-02-11 2017-11-22 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN107381970A (en) * 2017-09-09 2017-11-24 威海威高血液净化制品有限公司 One kind dialysis effluent purifying device
CN114173841A (en) * 2019-07-09 2022-03-11 环球油品有限责任公司 Method for removing Hg2+ from body fluids
CN115554975A (en) * 2022-10-13 2023-01-03 中南大学 Adsorbing material and preparation method and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
MX360684B (en) * 2012-10-22 2018-11-13 Zs Pharma Inc Microporous zirconium silicate for treating hyperkalemia.
ES2943007T3 (en) * 2013-04-05 2023-06-08 Zs Pharma Inc Microporous zirconium silicate and diuretics for potassium depletion and treatment of chronic kidney disease and/or chronic heart disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046971A1 (en) 1980-08-27 1982-03-10 Union Carbide Corporation Removal of uremic substances with zeolite ion-exchangers
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
US5536412A (en) 1992-02-06 1996-07-16 Hemocleanse, Inc. Hemofiltration and plasmafiltration devices and methods
US5891417A (en) * 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
EP0046971A1 (en) 1980-08-27 1982-03-10 Union Carbide Corporation Removal of uremic substances with zeolite ion-exchangers
US5536412A (en) 1992-02-06 1996-07-16 Hemocleanse, Inc. Hemofiltration and plasmafiltration devices and methods
US5891417A (en) * 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7920884B2 (en) 2004-06-04 2011-04-05 Qualcomm Incorporated Frame structures for a wireless communication system with multiple radio technologies
US8089855B2 (en) 2004-06-04 2012-01-03 Qualcomm Incorporated Transmission of overhead information for broadcast and multicast services in a wireless communication system
US8687617B2 (en) 2004-06-04 2014-04-01 Qualcomm Incorporated Wireless communication system with improved broadcast coverage
US8640887B2 (en) 2008-10-03 2014-02-04 Fresenius Medical Care Holdings, Inc. Zirconium phosphate particles having improved adsorption capacity and method of synthesizing the same
US8733559B2 (en) 2008-10-03 2014-05-27 Fresenius Medical Care Holdings, Inc. Zirconium phosphate particles having improved adsorption capacity and method of synthesizing the same
US9296611B2 (en) 2008-10-03 2016-03-29 Fresenius Medical Care Holdings, Inc. Zirconium phosphate particles having improved adsorption capacity and method of synthesizing the same
EP3246287A1 (en) * 2011-02-11 2017-11-22 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN107381970A (en) * 2017-09-09 2017-11-24 威海威高血液净化制品有限公司 One kind dialysis effluent purifying device
CN107381970B (en) * 2017-09-09 2022-11-29 山东威高血液净化制品股份有限公司 Dialysis waste liquid purifier
CN114173841A (en) * 2019-07-09 2022-03-11 环球油品有限责任公司 Method for removing Hg2+ from body fluids
CN115554975A (en) * 2022-10-13 2023-01-03 中南大学 Adsorbing material and preparation method and application thereof
CN115554975B (en) * 2022-10-13 2023-07-21 中南大学 Adsorption material and preparation method and application thereof

Also Published As

Publication number Publication date
JP2004502508A (en) 2004-01-29
EP1307270A1 (en) 2003-05-07
AU2000260501A1 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
US6332985B1 (en) Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US6099737A (en) Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6579460B1 (en) Process and composition for removing toxins from bodily fluids
CA2427985C (en) Cartridges useful in cleaning dialysis solutions
US7033498B2 (en) Cartridges useful in cleaning dialysis solutions
CA2678390C (en) Acid zirconium phosphate and alkaline hydrous zirconium oxide materials for sorbent dialysis
AU2002217930A1 (en) Cartridges useful in cleaning dialysis solutions
EP0003914A2 (en) Dialysis composition
WO2002004086A1 (en) Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US11577014B2 (en) Process for removing strontium ions from bodily fluids using metallate ion exchange compositions
US11484875B2 (en) Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions
US20220096962A1 (en) Process for removing lead, mercury, potassium, and ammonium ions from bodily fluids using rare-earth silicate ion exchange compositions
US20220097019A1 (en) Process for removing lead ions from boldily fluids using metallate ion exchange compositions
US20210008266A1 (en) Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions
WO2023101606A2 (en) Sorbent for dialysis and sorbent system for regenerative dialysis
WO2022251494A1 (en) Sorbent regeneration cartridge for dialysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2000946802

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000946802

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000946802

Country of ref document: EP